PBSV : Summary for PHARMA-BIO SERVICE COM STK USD0 - Yahoo Finance

U.S. Markets closed

Pharma-Bio Serv, Inc. (PBSV)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.870.00 (0.00%)
At close: 2:24 PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.87
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,976
Market Cap20.02M
Beta0.21
PE Ratio (TTM)26.36
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pharma-Bio Serv, Inc.: Strong price momentum but will it sustain?
    Capital Cube26 days ago

    Pharma-Bio Serv, Inc.: Strong price momentum but will it sustain?

    Categories: Yahoo Finance Pharma-Bio Serv, Inc. relative valuation is UNDERVALUED and it has a fundamental analysis score of 41. Our analysis is based on comparing Pharma-Bio Serv, Inc. with the following peers – Willdan Group, Inc., ExlService Holdings, Inc., NV5 Global Inc and Intertech Solutions Inc. (WLDN-US, EXLS-US, NVEE-US and ITEC-US). Pharma-Bio Serv, Inc.’s one year price performance ... Read more (Read more...)

  • Pharma-Bio Serv, Inc. :PBSV-US: Earnings Analysis: Q3, 2016 By the Numbers : September 19, 2016
    Capital Cube2 months ago

    Pharma-Bio Serv, Inc. :PBSV-US: Earnings Analysis: Q3, 2016 By the Numbers : September 19, 2016

    Categories: Yahoo Finance Get free summary analysis Pharma-Bio Serv, Inc. reports financial results for the quarter ended July 31, 2016. We analyze the earnings along side the following peers of Pharma-Bio Serv, Inc. – Willdan Group, Inc., ExlService Holdings, Inc. and NV5 Global Inc (WLDN-US, EXLS-US and NVEE-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • Zacks Small Cap Research3 months ago

    PBSV: Lab Segment Remains Robust Reflecting Opportunistic Investments

    Pharma-Bio Serv, Inc. (PBSV) reported financial results for their third quarter ending July 31, 2016.  While results on the top-line remain on the tepid side with revenue contracting on a year-over-year basis for 11 straight quarters, the company continues to generate positive operating cash flow.  And this is despite PBSV making incremental investments in headcount (as well as capital investments in lab facilities). The company's business model allows for significant flexibility, however, and we expect PBSV to continue to be opportunistic and dedicate a greater portion of resources where they see the most opportunity for growth.  The lab segment clearly appears to be one of those areas.  Lab-related revenue now accounts for 12.5% of total sales, up from just 7.5% through the first nine months of 2015, and this could expand further.  As a reminder, PBSV previously announced an expected aggregate investment of approximately $2M to expand its lab facilities - $1.1M has already been invested and, per the current 10-Q footnotes, the remaining ~$900k is expected to be allocated by fiscal year-end (i.e.